文献速递骨质疏松与代谢性骨病

在基于登记数据的队列研究中比较唑来膦酸、伊班膦酸和阿仑膦酸与地舒单抗的抗骨折有效性

Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
PubMed 文献 · Osteoporos Int · 2023-07-26

这项基于登记数据的队列研究纳入3068例骨质疏松患者,比较地舒单抗与双膦酸盐的抗骨折有效性。校正年龄、基线T值和骨小梁评分后,地舒单抗相比阿仑膦酸或伊班膦酸与椎体骨折和任何骨折风险降低显著相关;唑来膦酸与地舒单抗之间未发现骨折风险降低的差异。

要点

  • 地舒单抗相比阿仑膦酸或伊班膦酸与椎体骨折和任何骨折风险降低显著相关
  • 唑来膦酸与地舒单抗之间未发现椎体、非椎体或髋部骨折风险降低的差异
  • 所有双膦酸盐、地舒单抗和药物假期的椎体、非椎体和髋部骨折风险均显著低于治疗开始前

核心结论

  • 校正疾病严重程度后,地舒单抗相比阿仑膦酸和伊班膦酸与椎体骨折风险降低显著相关。
  • 唑来膦酸与地舒单抗之间未发现骨折风险降低的差异。

研究设计与样本

  • 这项基于登记数据的队列研究纳入3068例骨质疏松患者(89%为女性;治疗开始时中位年龄69岁[63至76])。
  • 患者接受地舒单抗(中位持续时间2.8年[2.2至4.7])、双膦酸盐(3.4年[2.1至5.7])或两者序贯治疗。
  • 双膦酸盐评估了11078受试者年(41%阿仑膦酸、36%伊班膦酸、23%唑来膦酸),地舒单抗评估了4216受试者年。
  • 治疗开始前观察了48375受试者年,另有2593年药物假期。

主要发现

  • 50岁后共发生1481例椎体骨折(治疗期间435例)、1508例非椎体骨折(治疗期间499例)和202例髋部骨折(治疗期间67例)。
  • 所有双膦酸盐、地舒单抗和药物假期下椎体、非椎体和髋部骨折风险均显著低于治疗开始前(所有p < 0.001)。
  • 校正年龄、基线T值和骨小梁评分后,地舒单抗相比阿仑膦酸与椎体骨折风险降低相关(aHR 0.47[0.35至0.64],p < 0.001),相比伊班膦酸与椎体骨折风险降低相关(aHR 0.70[0.53至0.91],p = 0.009)。
  • 校正年龄、基线T值和骨小梁评分后,地舒单抗相比阿仑膦酸与任何骨折风险降低相关(aHR 0.62[0.51至0.76],p < 0.001),相比伊班膦酸与任何骨折风险降低相关(aHR 0.77[0.64至0.92],p = 0.004)。
  • 采用倾向评分加权时,地舒单抗相比阿仑膦酸与髋部骨折风险降低相关(HR 0.54[0.29至0.98],p = 0.044);唑来膦酸与地舒单抗之间未发现椎体、非椎体或髋部骨折风险降低的差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This registry-based study of 3068 patients with osteoporosis compared the anti-fracture effectiveness of denosumab versus bisphosphonates. Denosumab was associated with significantly greater risk reduction than alendronate or ibandronate for vertebral and any fractures. No difference in fracture risk reduction was found between zoledronate and denosumab. PURPOSE: To analyse the fracture risk of patients with osteoporosis receiving bisphosphonates or denosumab in a real-world setting. METHODS: This registry-based cohort study evaluated patients taking denosumab, bisphosphonates or both sequentially. Fractures were analysed using rates, rate ratios and hazard ratios (HR), including both therapies as time-varying co-variates. Fracture risk hazards were adjusted (aHR) for baseline T-Scores and trabecular bone score (TBS) and were additionally analysed with inverse probability treatment weighting. RESULTS: A total of 3068 patients (89% female; median age at treatment onset, 69 years [63 to 76]) received denosumab (median duration 2.8 years, [2.2 to 4.7]), bisphosphonates (3.4 years, [2.1 to 5.7]) or both sequentially. Thus, 11,078 subject-years were assessed for bisphosphonates (41% alendronate, 36% ibandronate, 23% zoledronate) and 4216 for denosumab. Moreover, 48,375 subject-years were observed before treatment onset, in addition to 2593 years of drug holidays. A total of 1481 vertebral fractures (435 under therapy), 1508 non-vertebral fractures (499 under therapy) and 202 hip fractures (67 under therapy) occurred after age 50. The risks of vertebral, non-vertebral and hip fractures were significantly lower under all bisphosphonates, denosumab and drug holidays than before treatment onset (all p < 0.001). After adjusting for age, baseline T-scores and TBS, denosumab was associated with lower risk than alendronate or ibandronate for vertebral fractures (aHR 0.47 (0.35 to 0.64) and 0.70 [0.53 to 0.91], p < 0.001 and p = 0.009, respectively) and any fractures (aHR 0.62 [0.51 to 0.76] and 0.77 [0.64 to 0.92], p < 0.001 and p = 0.004). With propensity weighting, denosumab was associated with a lower hip fracture risk compared to alendronate (HR 0.54 [0.29 to 0.98], p = 0.044). No difference in fracture risk reduction (vertebral, non-vertebral or hip) was found between zoledronate and denosumab. CONCLUSIONS: When adjusting for disease severity, denosumab was associated with significantly greater risk reduction than alendronate and ibandronate for vertebral fractures. No difference in fracture risk reduction was found between zoledronate and denosumab.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Everts-Graber J, Bonel H, Lehmann D, et al. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. Osteoporos Int. 2023. PMID: 37493978. doi:10.1007/s00198-023-06863-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。